Release Date: Wednesday, November 12, 2014
Expiration Date: Wednesday, November 11, 2015
This CME-certified on-demand activity, developed by David H. Ilson, MD, PhD, is based on frequently asked questions posed during presentations conducted by expert faculty at the live grand rounds entitled, “Emerging Research with Novel Targeted Therapies for the Treatment of Advanced Gastric Cancer,” at academic centers and medical institutions throughout the United States. This activity will allow participants to gain perspective on unanswered questions pertaining to the treatment of gastric cancer, including the effectiveness and appropriate use of HER2 targeted agents, as well as a recently approved VEGFR-2 targeted agent for second-line therapy.
To access this activity, please click the ‘Download Activity' button above.
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above
For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
This activity is designed for medical oncologists, surgical oncologists, gastroenterologists, radiation oncologists, pathologists, and other healthcare professionals involved in the treatment of patients with gastric cancer.
At the conclusion of this activity, participants should be able to:
Describe the role of HER2 in gastric cancer and the importance of HER2 testing in selecting treatment for HER2-positive gastric cancer patients
Assess current evidence supporting the use of HER2-targeted agents for the treatment of gastric cancer
Evaluate recent trial data for novel targeted agents being explored for the first and second-line treatment of patients with gastric cancer
Describe how novel targeted agents may be integrated into treatment strategies for patients with advanced gastric cancer
Identify current clinical trials with novel targeted agents for gastric cancer
Physician Continuing Medical Education
ACCME Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and AXIS Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement
The Medical College of Wisconsin designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Consistent with the current Accreditation Council for Continuing Medical Education policy, the CME Provider must be able to show that everyone who is in a position to control the content of an individual educational activity has disclosed all relevant financial relationships. The CME Provider has a mechanism in place to identify and resolve any conflicts of interest discovered in the disclosure process. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant:
David H. Ilson, MD, PhD, reported a financial interest/relationship or affiliation in the form of: Contracted Research, Amgen, Inc., Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company; Consultant, Eli Lilly and Company, ImClone LLC.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
Upon successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Jointly provided by
This activity is supported by an educational grant from Lilly USA, LLC.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com